Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
about
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targetsAn Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of CholangiocarcinomaCholangiocarcinomaMolecular profiling of biliary tract cancer: a target rich diseasePathology of intrahepatic cholangiocarcinoma.Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma.Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.Molecular pathogenesis of cholangiocarcinoma.Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic targetA patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.Pathogenesis, diagnosis, and management of cholangiocarcinomaPeriostin in intrahepatic cholangiocarcinoma: pathobiological insights and clinical implications.Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.Cholangiocarcinoma: molecular pathways and therapeutic opportunitiesIntensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinomaTumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry.Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma.Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinomaBRAF V600E mutational status in bile duct adenomas and hamartomas.Molecular diagnosis of intrahepatic cholangiocarcinoma.Lipopolysaccharide (LPS)-Induced Biliary Epithelial Cell NRas Activation Requires Epidermal Growth Factor Receptor (EGFR).Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic CholangiocarcinomaLiver cancer oncogenomics: opportunities and dilemmas for clinical applications.Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma.Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma.Molecular genetics and targeted therapeutics in biliary tract carcinoma.Delivery of miR-200c Mimic with Poly(amido amine) CXCR4 Antagonists for Combined Inhibition of Cholangiocarcinoma Cell Invasiveness.New insights into the molecular pathogenesis of intrahepatic cholangiocarcinomaStaging of intrahepatic cholangiocarcinoma.Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.Hydrodynamic transfection for generation of novel mouse models for liver cancer research.Molecular pathogenesis of intrahepatic cholangiocarcinoma.New Horizons for Precision Medicine in Biliary Tract Cancers.Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line.
P2860
Q26751224-9D2606B9-48EC-4F69-BED3-235CB04BDB65Q26784091-87C57715-644E-40F9-945B-0E62AEF93CC1Q27001694-7F167D06-7A33-463D-AFF5-61EEF661981EQ28072275-D4279583-6B74-40B7-A231-883AA65FC00CQ30235427-0725544A-0D80-414D-B329-B6981D716DD8Q30405398-2B9C95EF-0B85-4500-A3EF-8372925ABC1AQ33757122-8EBC700A-32C0-4389-8BAF-A7232059721FQ33845409-70DAFD05-3A83-437E-819A-97CA52AA3BDEQ33936179-48ADECD4-BDA0-4B1C-87A5-D3296196DDE1Q34065560-A5BB15AC-3995-4123-90F2-AB13A0C5BF0AQ34079007-87F1D54C-E0C9-47D9-8FC8-FD3DA74F4C56Q34365897-E813BEC4-1AE2-4FD0-A8B6-439FD9128E9CQ34484245-715E8F07-8C3B-41E2-9EEE-E6F5FBDCABC3Q34656747-18E741C0-9B70-43E3-A306-4F984E9123DBQ34673957-929D3748-29A0-4C0A-B51B-A459818C43E5Q34764681-466B978F-0A4C-43B6-8545-5127F631749BQ34959174-21062568-21B9-49C0-875E-37F53AB78261Q35029031-EE8EDC1C-8D12-4817-8CED-A06430FE0692Q35134122-716905EB-BF1A-4D65-9881-2BC935AE3922Q35181521-23F11610-A414-4D98-858D-BBD75A0F049DQ35215602-D13ED1CD-F2C1-4048-9672-E96A5F87EB16Q35565384-EEC1FA66-ECA3-4E8E-B8B0-CC557E32E315Q35592221-38C59EC7-E6FE-46D0-9998-1A27CAC0C78CQ35615198-7A006082-F318-4078-8E20-E1E58F7DC0FCQ35674607-C277FE9D-40D6-48B4-BE49-A72F57333F0BQ35873406-E6D59493-B637-4869-BDF1-83B960AA21C0Q35913384-7313C41C-6AE0-4D30-A39A-85D988A8B316Q36278688-6C2A0F92-0146-4459-8EBA-AD3063BF0C38Q36326283-B22737F2-0844-4CD6-B166-1C38350CD7FFQ36414244-96BAA3A0-2B4F-45FD-9035-BD887E6B49E2Q36488070-BBD1655D-0A74-41DA-A915-9335168DBCD6Q37045471-356450BB-7C25-460B-85AA-FFF410708F31Q37621790-17BD7DAA-D381-4B04-8E9B-EC96F78997E1Q37675065-28DAE7F9-6A4E-41C0-A4C0-DF8B5C2941EEQ37688923-A374A8DB-46E8-4DC5-A8EA-70F283C389A6Q37719383-3704FB07-0063-48CD-91F5-7A0BBC42AE1AQ38183539-20522A5D-B518-4DB9-9CD3-D6D9BFFEF774Q38244965-0524E5F1-BE64-4A74-B377-1E545DC3148AQ38619219-D03E4CE7-8BF3-4F30-8F4A-195C61040FD1Q38728270-BAB2EEC7-C112-4914-98DB-8882F3CAD8A9
P2860
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@ast
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@en
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@nl
type
label
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@ast
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@en
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@nl
prefLabel
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@ast
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@en
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@nl
P2093
P2860
P3181
P356
P1433
P1476
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies
@en
P2093
P2860
P2888
P304
P3181
P356
10.1038/ONC.2012.617
P407
P577
2013-10-10T00:00:00Z
P6179
1020016247